12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sofosbuvir: Additional Phase IIb data

Data from 4 arms in the U.S. Phase IIb ELECTRON trial showed that all 85 evaluable patients receiving sofosbuvir plus ribavirin for 8 or 12 weeks achieved a rapid virologic response (RVR) at week 4 of treatment with no on-treatment viral breakthroughs observed. Specifically, treatment-naïve patients with HCV genotype 2 and 3 infection (n=25) who received 8 weeks of treatment, null responders with HCV genotype 1 infection (n=10), treatment-naïve patients with HCV genotype 1 infection (n=25) and treatment-experienced patients with HCV genotype 2 and 3 infection (n=25) who received 12 weeks of treatment achieved an RVR at week 4. Additionally, 1 null responder with HCV genotype 1 infection achieved an SVR defined as undetectable HCV RNA levels (<15 IU/mL) 12 weeks after completing 12 weeks of treatment. The other 9 null responders in the cohort relapsed prior to post-treatment week 4. Furthermore, 18 of 24 evaluable treatment-experienced patients with HCV genotype 2 and...

Read the full 742 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >